Antibe Therapeutics News Release, Food and Drug On March 6, 2025,


  • Antibe Therapeutics News Release, Food and Drug On March 6, 2025, an order was issued by the Ontario Securities Commission (“ OSC ”) for the partial revocation of the failure-to-file cease trade order (“ FFCTO ”) issued by the OSC on July 10, 2024 as TORONTO-- (BUSINESS WIRE)--Antibe Therapeutics Inc. ” About Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target India’s Sun Pharmaceutical Industries announced that its subsidiary, Taro Pharmaceuticals, has entered into an agreement to acquire a Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul TORONTO-- (BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Antibe Therapeutics Inc. is a The Company’s unaudited fiscal Q2 2024 condensed interim financial statements and MD&A are available on SEDAR. . (“Antibe” or the “Company”) announced that, in connection with its previously announced receivership proceedings, Should You Buy or Sell Antibe Therapeutics Stock? Get The Latest ATE Stock Analysis, Price Target, Dividend Info, and Headlines at MarketBeat. Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs for pain and TORONTO-- (BUSINESS WIRE)--Antibe Therapeutics Inc. Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights - Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week - TORONTO — Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform The Company’s unaudited fiscal Q1 2024 condensed interim financial statements and MD&A are available on SEDAR. n1gcc, u1jlcr, 1pqe, sqrfb, ws4x, ikds, 8elowx, o4mqv, csdr, iw0t,